New hope for stomach cancer: drug combo shows promise in Real-World study

NCT ID NCT07427992

First seen Feb 24, 2026 · Last updated May 06, 2026 · Updated 8 times

Summary

This study looks at how well a drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The cancer must have a specific protein (claudin 18.2) on its surface. The goal is to see if the combination can help control the disease longer. About 70 adults will take part, and they will receive the treatment as part of their regular care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • European Institute of Oncology

    RECRUITING

    Milan, 20141, Italy

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.